During my MSc, I developed a machine learning-based predictor of peptide sequence detectability in mass spectrometry for application to targeted proteomics strategies. I also performed proteome profiling on a large cohort of Mantle Cell Lymphoma tumours, leading to the identification of novel molecular subgroups and clinical associations in the disease.
In July 2025, I joined Rik Lindeboom's and Michiel Vermeulen’s labs to develop single cell proteomics pipelines and apply them to rare tumours within the RADAR consortium. Using this technology, we hope to uncover insights on the role of intratumoural heterogeneity in rare cancers.